Patents by Inventor Jerome Braudeau

Jerome Braudeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alzheimer's disease animal model
    Patent number: 10986821
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: April 27, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Paris—Sud, Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • NEW ALZHEIMER'S DISEASE ANIMAL MODEL
    Publication number: 20190183102
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Application
    Filed: November 2, 2018
    Publication date: June 20, 2019
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • Alzheimer's disease animal model
    Patent number: 10159227
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 25, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Paris—Sud, Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20180161395
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for a polypeptide which is a soluble member of the APP (amyloid precursor protein) family.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 14, 2018
    Inventors: Romain FOL, Jerome BRAUDEAU, Nathalie CARTIER, Christian BUCHHOLZ, Abel TOBIAS, Ulrike MUELLER
  • NEW ALZHEIMER'S DISEASE ANIMAL MODEL
    Publication number: 20160262361
    Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 15, 2016
    Inventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
  • USE OF FUSION PROTEINS FOR THE PREVENTION OR THE TREATMENT OF PATHOLOGIES RESULTING FROM ISCHEMIA
    Publication number: 20090118180
    Abstract: The present invention relates to the use of a fusion protein including a peptide sequence having membrane transducing properties, and a peptide sequence having cell survival properties, or a nucleic acid coding for the fusion protein, for the manufacture of a medicament intended for the prevention or the treatment of pathologies resulting from ischemia.
    Type: Application
    Filed: September 29, 2006
    Publication date: May 7, 2009
    Applicant: Institut National De La Sante ET De La Recherche Medicale (Inserm)
    Inventors: Brigitte Onteniente, Christelle Guegan, Jerome Braudeau, Cecile Couriaud